Conde-Agudelo Agustín, Romero Roberto
Perinatology Research Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
Am J Obstet Gynecol. 2009 Jun;200(6):595-609. doi: 10.1016/j.ajog.2009.04.005.
We conducted a systematic review and metaanalysis of randomized controlled trials to determine whether magnesium sulfate administered to women at risk of preterm delivery before 34 weeks of gestation may reduce the risk of cerebral palsy in their children. Six trials involving 4796 women and 5357 infants were included. Antenatal magnesium sulfate was associated with a significant reduction in the risk of cerebral palsy (relative risk [RR], 0.69; 95% confidence interval [CI], 0.55-0.88), moderate or severe cerebral palsy (RR, 0.64; 95% CI, 0.44-0.92), and substantial gross motor dysfunction (RR, 0.60; 95% CI, 0.43-0.83). There was no overall difference in the risk of total pediatric mortality (RR, 1.01; 95% CI, 0.89-1.14). Minor side effects were more frequent among women receiving magnesium sulfate. In conclusion, magnesium sulfate administered to women at risk of delivery before 34 weeks of gestation reduces the risk of cerebral palsy.
我们进行了一项随机对照试验的系统评价和荟萃分析，以确定在妊娠34周前对有早产风险的妇女使用硫酸镁是否可降低其子女患脑瘫的风险。纳入了六项涉及4796名妇女和5357名婴儿的试验。产前使用硫酸镁与脑瘫风险显著降低相关（相对风险[RR]，0.69；95%置信区间[CI]，0.55 - 0.88），中重度脑瘫风险降低（RR，0.64；95%CI，0.44 - 0.92），以及严重粗大运动功能障碍风险降低（RR，0.60；95%CI，0.43 - 0.83）。儿童总死亡率风险无总体差异（RR，1.01；95%CI，0.89 - 1.14）。接受硫酸镁治疗的妇女中轻微副作用更常见。总之，在妊娠34周前对有分娩风险的妇女使用硫酸镁可降低脑瘫风险。
